A View from the Wellcome Trust Drug-Resistant Infections Priority Programme: Creating a Sustainable Research and Development Ecosystem to Meet the Global Need for Antibiotics

  15 June 2020

Antibiotics have been a key component of modern medicine for decades. A critical question is why not enough antibacterials are being developed to tackle the growing challenge of drug-resistant infections. While current innovation in the early preclinical pipeline is encouraging, the journey for any new antibiotic is burdened with multiple challenges across its early and late development path. In this viewpoint, we explore the barriers to antibiotic development and how the Wellcome Trust is addressing these problems and working toward developing long-term solutions to facilitate a sustainable R&D ecosystem.

Further reading: ACS Publications
Author(s): Joanna Wiecek and Gemma Buckland-Merrett
Smart Innovations  
Back

OUR UNDERWRITERS

Unrestricted financial support kindly provided by

Antimicrobial Resistance Fighter Coalition

CDD VAULT Complexity Simplified





Technology Database

Display your AMR Technology, Product and Service

Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.

Read more and make your own Technology Page >>
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!